BIRMINGHAM, Ala.--(BUSINESS WIRE)--Researchers using the VAP® Cholesterol Test to isolate lipid subfractions and assess a new anti-flushing agent report significant baseline reductions in the cholesterol content of lipoproteins across the entire VLDL to LDL density range in dyslipidemic patients.
